10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence: a prospective cohort study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Smoking is a major risk factor for bladder cancer, but the relationship between smoking cessation after initial treatment and bladder cancer recurrence has been investigated less frequently and not prospectively yet.

          Methods

          722 non-muscle-invasive bladder cancer (NMIBC) patients (pTa, pT1, and CIS) from the prospective Bladder Cancer Prognosis Programme (BCPP) cohort, selected in the UK between 2005 and 2011, provided complete data on smoking behavior before and up to 5 years after diagnosis. The impact of smoking behavior on NMIBC recurrence was explored by multivariable Cox regression models investigating time-to-first NMIBC recurrence.

          Results

          Over a median follow-up period of 4.21 years, 403 pathologically confirmed NMIBC recurrences occurred in 210 patients. Only 25 current smokers at diagnosis quit smoking (14%) during follow-up and smoking cessation after diagnosis did not decrease risk of recurrence compared to continuing smokers ( p = 0.352).

          Conclusions

          Although quitting smoking after diagnosis might reduce the risk of recurrence based on retrospective evidence, this is not confirmed in this prospective study because the number of NMIBC patients quitting smoking before their first recurrence was too low. Nevertheless, this indicates an important role for urologists and other health care professionals in promoting smoking cessation in NMIBC.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: found
          • Article: not found

          Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

          To provide tables that allow urologists to easily calculate a superficial bladder cancer patient's short- and long-term risks of recurrence and progression after transurethral resection. A combined analysis was carried out of individual patient data from 2596 superficial bladder cancer patients included in seven European Organization for Research and Treatment of Cancer trials. A simple scoring system was derived based on six clinical and pathological factors: number of tumors, tumor size, prior recurrence rate, T category, carcinoma in situ, and grade. The probabilities of recurrence and progression at one year ranged from 15% to 61% and from less than 1% to 17%, respectively. At five years, the probabilities of recurrence and progression ranged from 31% to 78% and from less than 1% to 45%. With these probabilities, the urologist can discuss the different options with the patient to determine the most appropriate treatment and frequency of follow-up.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.

            Bladder cancer has become a common cancer globally, with an estimated 430 000 new cases diagnosed in 2012.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications.

              The concept of "field cancerization" was first introduced by Slaughter et al. [D. P, Slaughter et al., Cancer (Phila.), 6: 963-968, 1953] in 1953 when studying the presence of histologically abnormal tissue surrounding oral squamous cell carcinoma. It was proposed to explain the development of multiple primary tumors and locally recurrent cancer. Organ systems in which field cancerization has been described since then are: head and neck (oral cavity, oropharynx, and larynx), lung, vulva, esophagus, cervix, breast, skin, colon, and bladder. Recent molecular findings support the carcinogenesis model in which the development of a field with genetically altered cells plays a central role. In the initial phase, a stem cell acquires genetic alterations and forms a "patch," a clonal unit of altered daughter cells. These patches can be recognized on the basis of mutations in TP53, and have been reported for head and neck, lung, skin, and breast cancer. The conversion of a patch into an expanding field is the next logical and critical step in epithelial carcinogenesis. Additional genetic alterations are required for this step, and by virtue of its growth advantage, a proliferating field gradually displaces the normal mucosa. In the mucosa of the head and neck, as well as the esophagus, such fields have been detected with dimensions of >7 cm in diameter, whereas they are usually not detected by routine diagnostic techniques. Ultimately, clonal divergence leads to the development of one or more tumors within a contiguous field of preneoplastic cells. An important clinical implication is that fields often remain after surgery of the primary tumor and may lead to new cancers, designated presently by clinicians as "a second primary tumor" or "local recurrence," depending on the exact site and time interval. In conclusion, the development of an expanding preneoplastic field appears to be a critical step in epithelial carcinogenesis with important clinical consequences. Diagnosis and treatment of epithelial cancers should not only be focused on the tumor but also on the field from which it developed.
                Bookmark

                Author and article information

                Contributors
                +3143 388 1991 , f.vanosch@maastrichtuniversity.nl
                Journal
                Cancer Causes Control
                Cancer Causes Control
                Cancer Causes & Control
                Springer International Publishing (Cham )
                0957-5243
                1573-7225
                30 May 2018
                30 May 2018
                2018
                : 29
                : 7
                : 675-683
                Affiliations
                [1 ]ISNI 0000 0001 0481 6099, GRID grid.5012.6, Unit of Nutritional and Cancer Epidemiology, Chairgroup of Complex Genetics and Epidemiology, School for Nutrition and Translational Research in Metabolism (NUTRIM), , Maastricht University, ; Maastricht, The Netherlands
                [2 ]ISNI 0000 0004 1936 7486, GRID grid.6572.6, Institute of Cancer and Genomic Sciences, , University of Birmingham, ; Birmingham, UK
                [3 ]ISNI 0000 0004 1936 7486, GRID grid.6572.6, Department of Public Health and Epidemiology, , University of Birmingham, ; Birmingham, UK
                [4 ]ISNI 0000 0004 0376 6589, GRID grid.412563.7, University Hospital Birmingham, NHS Foundation Trust, ; Birmingham, UK
                [5 ]ISNI 0000 0001 0481 6099, GRID grid.5012.6, Department of Pharmacology and Toxicology, School for Nutrition and Translational Research in Metabolism (NUTRIM), , Maastricht University, ; Maastricht, The Netherlands
                [6 ]ISNI 0000 0001 0481 6099, GRID grid.5012.6, Chairgroup of Complex Genetics and Epidemiology, Care and Public Health Research Institute (CAPRHI), , Maastricht University, ; Maastricht, The Netherlands
                Author information
                http://orcid.org/0000-0003-4329-2560
                Article
                1046
                10.1007/s10552-018-1046-8
                5999150
                29846846
                0ceb41ab-718e-4d6a-8e68-d175c026e362
                © The Author(s) 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 6 April 2018
                : 28 May 2018
                Categories
                Original Paper
                Custom metadata
                © Springer International Publishing AG, part of Springer Nature 2018

                Oncology & Radiotherapy
                smoking,smoking cessation,bladder cancer,prognosis,recurrence,epidemiology
                Oncology & Radiotherapy
                smoking, smoking cessation, bladder cancer, prognosis, recurrence, epidemiology

                Comments

                Comment on this article

                scite_

                Similar content262

                Cited by9

                Most referenced authors442